Q
QuantAbundanceAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

30,634 signal articles · 26 in last 24h · 155,746 total before filter · latest 1h ago
26last 24h
848last 7d
142● bullish (7d)
89● bearish (7d)
214publishers
AllMacro195Earnings106M&A122Regulatory20Product21Analyst19
✕ clear all filtersticker: NVDASentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Should Lockheed’s AI Sensing and Space Partnerships Shift the Core Investment Case for LMT?
Simply Wall St.37d agobullish
Should Lockheed’s AI Sensing and Space Partnerships Shift the Core Investment Case for LMT?

In August 2026, Lockheed Martin and partners including Verizon, NVIDIA, Keysight Technologies, ODC and Astris AI showcased the NetSense Airspace Awareness-as-a-Service system, advanced NGI Stage 2 testing, expanded its Strigo modular defense solutions, and supported Firefly Aerospace’s extended launch agreement to enhance responsive space access. Together with over US$152 million in recent Department of Defense contracts and inclusion in a US$920 million Air Force award pool, these moves...

Own Too Much Nvidia? How to Deal With Capital Gains.
Barrons.com37d agoneutral
Own Too Much Nvidia? How to Deal With Capital Gains.

You could do a thought experiment to gauge your appetite for outsize holdings, says Cindy Wilson, a certified financial planner at HB Wealth in Alpharetta, Ga. For example, if a client was sitting on a $500,000 position in Apple Wilson would ask, what if they had $500,000 in cash instead? Before deciding whether to sell, consider how much capital-gains tax you may owe if you sell shares in a taxable account.

Why Regeneron (REGN) Is Up 5.4% After FDA Approves Pasatru For Ultra-Rare FOP Therapy
Simply Wall St.37d agoneutral
Why Regeneron (REGN) Is Up 5.4% After FDA Approves Pasatru For Ultra-Rare FOP Therapy

In August 2026, Regeneron Pharmaceuticals announced that the US FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and flare-ups in adults with fibrodysplasia ossificans progressiva, based on positive Phase 3 OPTIMA trial results. This approval adds a rare-disease monoclonal antibody to Regeneron’s portfolio, reinforcing the company’s focus on specialized, high-complexity immunology therapies. We’ll now examine how Pasatru’s FOP approval, as an ultra-rare...